Research graph
References from Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826). Local targets link to admitted publications; unresolved targets remain external evidence.
Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study
10.1182/blood-2004-09-3759 · 2005 · External reference
Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics
10.1002/ajh.24184 · 2015 · External reference
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma
10.1056/nejmoa0905680 · 2010 · External reference
Hodgkin lymphoma
10.1172/jci61245 · 2012 · External reference
Epstein-Barr virus in childhood and adolescent classic Hodgkin lymphoma in a French cohort of 301 patients
10.1097/mph.0000000000002403 · 2022 · External reference
Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients
10.1200/jco.2008.20.5138 · 2009 · External reference
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy
10.1158/1078-0432.ccr-11-1942 · 2012 · External reference
Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study
10.1200/jco.2005.02.6310 · 2005 · External reference
Treatment of Hodgkin lymphoma: the past, present, and future
10.1038/ncponc1186 · 2008 · External reference
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation
10.1038/sj.onc.1209151 · 2006 · External reference
Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma
10.1056/nejmoa2405888 · 2024 · External reference
Unresolved reference
2017 · External reference
Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma
10.1200/jco.23.01867 · 2024 · External reference
PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome
10.1200/jco.2016.66.4482 · 2016 · External reference
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
10.1182/blood-2010-05-282780 · 2010 · External reference
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
10.1056/nejmoa1411087 · 2015 · External reference
Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials
10.1016/s2352-3026(21)00349-5 · 2022 · External reference
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
10.3324/haematol.2021.278438 · 2022 · External reference
The advanced-stage Hodgkin Lymphoma International Prognostic Index: development and validation of a clinical prediction model from the HoLISTIC Consortium
10.1200/jco.22.02473 · 2023 · External reference
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
10.1016/s0140-6736(24)01315-1 · 2024 · External reference
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
10.1016/s1470-2045(21)00005-x · 2021 · External reference
